{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:17:41Z","timestamp":1791883061724,"version":"4.3.4"},"reference-count":16,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,6,20]]},"DOI":"10.18632\/oncotarget.28594","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:03:49Z","timestamp":1718888629000},"page":"408-417","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of FDG-PET\/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma"],"prefix":"10.18632","volume":"15","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[{"name":"Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kaida","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"2","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"38","author":"Gervais","year":"2016","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"3","author":"Janthur","year":"2020","journal-title":"Ann Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Allison","year":"2018","journal-title":"Cancer Discov"},{"key":"5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"2","author":"Urban","year":"2019","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"1","author":"Burgers","year":"2018","journal-title":"J Thorac Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Baas","year":"2019","journal-title":"Lancet Respir Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"39","author":"Cornelissen","year":"2021","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma","volume":"6","author":"Weber","year":"2019","journal-title":"J Nucl Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"1","author":"Nowak","year":"2004","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/cancers13051098","article-title":"Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT","volume":"1","author":"Yamakado","year":"2021","journal-title":"Cancers (Basel)"},{"key":"12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2009.04.015","article-title":"Combined FDG-PET\/CT in response evaluation of malignant pleural mesothelioma","volume":"6","author":"Stahel","year":"2010","journal-title":"Lung Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/MNM.0000000000001223","article-title":"Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma","volume":"4","author":"Yamakado","year":"2020","journal-title":"Nucl Med Commun"},{"key":"14","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00259-018-4008-1","article-title":"Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan","volume":"4","author":"Miyoshi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"4","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1148\/radiol.2282011860","article-title":"Measurement of observer agreement","volume":"22","author":"Polansky","year":"2003","journal-title":"Radiology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T16:37:27Z","timestamp":1718901447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6,20]]}},"alternative-id":["28594"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28594","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}